195
Participants
Start Date
February 28, 2009
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
UK-453, 061
UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
UK-453, 061
UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
EFV +TVA
Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
Pfizer Investigational Site, Namakgale
Pfizer Investigational Site, Darlinghurst
Pfizer Investigational Site, Soweto
Pfizer Investigational Site, Johannesburg
Pfizer Investigational Site, Melbourne
Pfizer Investigational Site, Durban
Pfizer Investigational Site, Lugano
Pfizer Investigational Site, Cape Town
Pfizer Investigational Site, Sankt Gallen
Pfizer Investigational Site, Torino
Pfizer Investigational Site, Mexico City
Pfizer Investigational Site, Milan
Pfizer Investigational Site, Milan
Pfizer Investigational Site, Buenos Aires
Pfizer Investigational Site, Toronto
Pfizer Investigational Site, Montreal
Pfizer Investigational Site, Montreal
Pfizer Investigational Site, Bydgoszcz
Pfizer Investigational Site, Gdansk
Pfizer Investigational Site, Lodz
Pfizer Investigational Site, Warsaw
Pfizer Investigational Site, Pretoria
Pfizer Investigational Site, Pretoria
Pfizer Investigational Site, Ch-8091 Zurich
Pfizer Investigational Site, Crumpsall
Pfizer Investigational Site, Brighton
Pfizer Investigational Site, Edinburgh
Pfizer Investigational Site, Edinburgh
Pfizer Investigational Site, London
Pfizer Investigational Site, London
Pfizer Investigational Site, London
Lead Sponsor
Pfizer
INDUSTRY